MGI 114: Augmentation of antitumor activity when combined with topotecan

Steven D Weitman, H. Barrera, R. Moore, C. Gonzalez, J. Marty, S. Hilsenbeck, J. R. MacDonald, S. J. Waters, D. Von Hoff

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: 6-Hydroxymethylacylfulvene (HMAF; MGI 114; Irofulven) is a semisynthetic analogue of the mushroom toxin illudin S that has been shown to be a potent cytotoxic agent with an improved therapeutic index compared with its parent compound. The studies were conducted to evaluate the antitumor activity of MGI 114 as a single agent and in combination with topotecan against pediatric solid tumor cell lines and xenograft models. Materials and Methods: In vitro studies were designed to determine the cytotoxic potential of MGI 114 using the MTT assay and 13 pediatric tumor cell lines. In addition, combination in vitro studies were performed with MGI 114 and topotecan to generate isoeffect plots. Single agent and combination in vivo studies were also performed using MGI 114 against rhabdomyosarcoma and neuroblastoma xenograft models. Results: After a 1-hour exposure to MGI 114, the mean IC50 (± standard error of mean) for medulloblastoma, neuroblastoma, Ewing sarcoma/primitive neuroectodermal tumor, and rhabdomyosarcoma cell lines were 1.58 ± 0.51, 1.60 ± 0.82, 1.18 ± 0.08, and 3.99 ± 1.69 μg/mL, respectively. When tumor cells were exposed concurrently to MGI 114 and topotecan, evidence of synergy was observed in 10 of 12 (83%) cell lines. Single agent and combination in vivo studies with MGI 114 showed that this agent had substantial, and at times curative, antitumor activity against rhabdomyosarcoma and neuroblastoma xenograft tumors. Conclusions: These data suggest that MGI 114 has significant efficacy as a single agent in preclinical studies against pediatric tumors. In addition, based on previous reports and the results presented here, combining MGI 114 with topotecan appears to be an attractive approach to the treatment of pediatric malignancies. After completion of the pediatric phase I studies of MGI 114, consideration should be given to phase II single agent and phase I combination studies with a topoisomerase I inhibitor such as topotecan or irinotecan.

Original languageEnglish (US)
Pages (from-to)306-314
Number of pages9
JournalJournal of Pediatric Hematology/Oncology
Volume22
Issue number4
DOIs
StatePublished - 2000

Fingerprint

Topotecan
Rhabdomyosarcoma
Pediatrics
Tumor Cell Line
Neuroblastoma
Heterografts
irinotecan
irofulven
Neoplasms
Topoisomerase I Inhibitors
Primitive Neuroectodermal Tumors
Medulloblastoma
Ewing's Sarcoma
Agaricales
Cytotoxins
Inhibitory Concentration 50

Keywords

  • HMAF
  • Illudins
  • MGI 114
  • Pediatric oncology
  • Synergy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Weitman, S. D., Barrera, H., Moore, R., Gonzalez, C., Marty, J., Hilsenbeck, S., ... Von Hoff, D. (2000). MGI 114: Augmentation of antitumor activity when combined with topotecan. Journal of Pediatric Hematology/Oncology, 22(4), 306-314. https://doi.org/10.1097/00043426-200007000-00006

MGI 114 : Augmentation of antitumor activity when combined with topotecan. / Weitman, Steven D; Barrera, H.; Moore, R.; Gonzalez, C.; Marty, J.; Hilsenbeck, S.; MacDonald, J. R.; Waters, S. J.; Von Hoff, D.

In: Journal of Pediatric Hematology/Oncology, Vol. 22, No. 4, 2000, p. 306-314.

Research output: Contribution to journalArticle

Weitman, SD, Barrera, H, Moore, R, Gonzalez, C, Marty, J, Hilsenbeck, S, MacDonald, JR, Waters, SJ & Von Hoff, D 2000, 'MGI 114: Augmentation of antitumor activity when combined with topotecan', Journal of Pediatric Hematology/Oncology, vol. 22, no. 4, pp. 306-314. https://doi.org/10.1097/00043426-200007000-00006
Weitman, Steven D ; Barrera, H. ; Moore, R. ; Gonzalez, C. ; Marty, J. ; Hilsenbeck, S. ; MacDonald, J. R. ; Waters, S. J. ; Von Hoff, D. / MGI 114 : Augmentation of antitumor activity when combined with topotecan. In: Journal of Pediatric Hematology/Oncology. 2000 ; Vol. 22, No. 4. pp. 306-314.
@article{947a5a519168477c886f486de3db27b6,
title = "MGI 114: Augmentation of antitumor activity when combined with topotecan",
abstract = "Purpose: 6-Hydroxymethylacylfulvene (HMAF; MGI 114; Irofulven) is a semisynthetic analogue of the mushroom toxin illudin S that has been shown to be a potent cytotoxic agent with an improved therapeutic index compared with its parent compound. The studies were conducted to evaluate the antitumor activity of MGI 114 as a single agent and in combination with topotecan against pediatric solid tumor cell lines and xenograft models. Materials and Methods: In vitro studies were designed to determine the cytotoxic potential of MGI 114 using the MTT assay and 13 pediatric tumor cell lines. In addition, combination in vitro studies were performed with MGI 114 and topotecan to generate isoeffect plots. Single agent and combination in vivo studies were also performed using MGI 114 against rhabdomyosarcoma and neuroblastoma xenograft models. Results: After a 1-hour exposure to MGI 114, the mean IC50 (± standard error of mean) for medulloblastoma, neuroblastoma, Ewing sarcoma/primitive neuroectodermal tumor, and rhabdomyosarcoma cell lines were 1.58 ± 0.51, 1.60 ± 0.82, 1.18 ± 0.08, and 3.99 ± 1.69 μg/mL, respectively. When tumor cells were exposed concurrently to MGI 114 and topotecan, evidence of synergy was observed in 10 of 12 (83{\%}) cell lines. Single agent and combination in vivo studies with MGI 114 showed that this agent had substantial, and at times curative, antitumor activity against rhabdomyosarcoma and neuroblastoma xenograft tumors. Conclusions: These data suggest that MGI 114 has significant efficacy as a single agent in preclinical studies against pediatric tumors. In addition, based on previous reports and the results presented here, combining MGI 114 with topotecan appears to be an attractive approach to the treatment of pediatric malignancies. After completion of the pediatric phase I studies of MGI 114, consideration should be given to phase II single agent and phase I combination studies with a topoisomerase I inhibitor such as topotecan or irinotecan.",
keywords = "HMAF, Illudins, MGI 114, Pediatric oncology, Synergy",
author = "Weitman, {Steven D} and H. Barrera and R. Moore and C. Gonzalez and J. Marty and S. Hilsenbeck and MacDonald, {J. R.} and Waters, {S. J.} and {Von Hoff}, D.",
year = "2000",
doi = "10.1097/00043426-200007000-00006",
language = "English (US)",
volume = "22",
pages = "306--314",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - MGI 114

T2 - Augmentation of antitumor activity when combined with topotecan

AU - Weitman, Steven D

AU - Barrera, H.

AU - Moore, R.

AU - Gonzalez, C.

AU - Marty, J.

AU - Hilsenbeck, S.

AU - MacDonald, J. R.

AU - Waters, S. J.

AU - Von Hoff, D.

PY - 2000

Y1 - 2000

N2 - Purpose: 6-Hydroxymethylacylfulvene (HMAF; MGI 114; Irofulven) is a semisynthetic analogue of the mushroom toxin illudin S that has been shown to be a potent cytotoxic agent with an improved therapeutic index compared with its parent compound. The studies were conducted to evaluate the antitumor activity of MGI 114 as a single agent and in combination with topotecan against pediatric solid tumor cell lines and xenograft models. Materials and Methods: In vitro studies were designed to determine the cytotoxic potential of MGI 114 using the MTT assay and 13 pediatric tumor cell lines. In addition, combination in vitro studies were performed with MGI 114 and topotecan to generate isoeffect plots. Single agent and combination in vivo studies were also performed using MGI 114 against rhabdomyosarcoma and neuroblastoma xenograft models. Results: After a 1-hour exposure to MGI 114, the mean IC50 (± standard error of mean) for medulloblastoma, neuroblastoma, Ewing sarcoma/primitive neuroectodermal tumor, and rhabdomyosarcoma cell lines were 1.58 ± 0.51, 1.60 ± 0.82, 1.18 ± 0.08, and 3.99 ± 1.69 μg/mL, respectively. When tumor cells were exposed concurrently to MGI 114 and topotecan, evidence of synergy was observed in 10 of 12 (83%) cell lines. Single agent and combination in vivo studies with MGI 114 showed that this agent had substantial, and at times curative, antitumor activity against rhabdomyosarcoma and neuroblastoma xenograft tumors. Conclusions: These data suggest that MGI 114 has significant efficacy as a single agent in preclinical studies against pediatric tumors. In addition, based on previous reports and the results presented here, combining MGI 114 with topotecan appears to be an attractive approach to the treatment of pediatric malignancies. After completion of the pediatric phase I studies of MGI 114, consideration should be given to phase II single agent and phase I combination studies with a topoisomerase I inhibitor such as topotecan or irinotecan.

AB - Purpose: 6-Hydroxymethylacylfulvene (HMAF; MGI 114; Irofulven) is a semisynthetic analogue of the mushroom toxin illudin S that has been shown to be a potent cytotoxic agent with an improved therapeutic index compared with its parent compound. The studies were conducted to evaluate the antitumor activity of MGI 114 as a single agent and in combination with topotecan against pediatric solid tumor cell lines and xenograft models. Materials and Methods: In vitro studies were designed to determine the cytotoxic potential of MGI 114 using the MTT assay and 13 pediatric tumor cell lines. In addition, combination in vitro studies were performed with MGI 114 and topotecan to generate isoeffect plots. Single agent and combination in vivo studies were also performed using MGI 114 against rhabdomyosarcoma and neuroblastoma xenograft models. Results: After a 1-hour exposure to MGI 114, the mean IC50 (± standard error of mean) for medulloblastoma, neuroblastoma, Ewing sarcoma/primitive neuroectodermal tumor, and rhabdomyosarcoma cell lines were 1.58 ± 0.51, 1.60 ± 0.82, 1.18 ± 0.08, and 3.99 ± 1.69 μg/mL, respectively. When tumor cells were exposed concurrently to MGI 114 and topotecan, evidence of synergy was observed in 10 of 12 (83%) cell lines. Single agent and combination in vivo studies with MGI 114 showed that this agent had substantial, and at times curative, antitumor activity against rhabdomyosarcoma and neuroblastoma xenograft tumors. Conclusions: These data suggest that MGI 114 has significant efficacy as a single agent in preclinical studies against pediatric tumors. In addition, based on previous reports and the results presented here, combining MGI 114 with topotecan appears to be an attractive approach to the treatment of pediatric malignancies. After completion of the pediatric phase I studies of MGI 114, consideration should be given to phase II single agent and phase I combination studies with a topoisomerase I inhibitor such as topotecan or irinotecan.

KW - HMAF

KW - Illudins

KW - MGI 114

KW - Pediatric oncology

KW - Synergy

UR - http://www.scopus.com/inward/record.url?scp=0034456925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034456925&partnerID=8YFLogxK

U2 - 10.1097/00043426-200007000-00006

DO - 10.1097/00043426-200007000-00006

M3 - Article

C2 - 10959900

AN - SCOPUS:0034456925

VL - 22

SP - 306

EP - 314

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -